Atossa settles patent disputes with Intas; Endoxifen patents remain enforceable

ATOSSA THERAPEUTICS, INC.

Entered Settlement Agreement on April 13, 2026 with Intas Pharmaceuticals and Jina Pharmaceuticals to resolve Endoxifen patent disputes.
PTAB proceedings will be terminated; U.S. Patent Nos. 11,261,151 and 12,071,391 remain issued and enforceable.
Mutual covenants prevent parties from challenging each other's specified Endoxifen patents and applications.
Agreement preserves Atossa's ability to develop and commercialize Z-endoxifen base in oncology, endocrine disorders, and muscular dystrophy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.